Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
Patent 4557934 Issued on December 10, 1985. Estimated Expiration Date: 
June 21, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 21, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 1974 296706 383391 506273 506274 2990331 3535422 Pharmaceutical composition Vehicle composition containing 1-substituted azacycloheptan-2-ones Potentiated medicaments InventorAssigneeApplicationNo. 06/506275 filed on 06/21/1983US Classes:514/159, Ortho-hydroxybenzoic acid (i.e., salicyclic acid) or derivative DOAI424/449, Transdermal or percutaneous424/601, Phosphorus or phosphorus compound514/165, Aspirin per se (i.e., 2-(acetyloxy)benozic acid)514/223.5, With additional active ingredient514/224.2, Polycyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,3- and 1,4- benzothiazines, etc.)514/224.5, At least three cyclos in the polycyclo ring system514/226.8, 1,3-Thiazines514/231.2, Morpholines (i.e., fully hydrogenated 1,4- oxazines)514/233.2, Ring nitrogen shared by two of the cyclos514/236.2, Three or more ring hetero atoms in the additional hetero ring514/270, Barbituric acid or derivative (including thioanalogs)514/374, 1,3-oxazoles (including hydrogenated)514/399, Chalcogen or nitrogen bonded indirectly to the imidazole ring by nonionic bonding514/635, Biguanides (i.e., N=C(-N)-N(N-)C=N)514/947Topical applicationExaminersPrimary: Roberts, Elbert L.Attorney, Agent or FirmInternational ClassesA61K 47/22 (20060101)A61K 31/57 (20060101) AbstractImproved topical pharmaceutical compositions containing a pharmaceutically-active agent and the penetration enhancing agent 1-dodecylazacycloheptan-2-one are disclosed. This agent is used at selected levels in combination with certain C3 -C4 diols or a 1-substituted azacycloalkyl-2-one. This composition provides marked transepidermal and percutaneous delivery of the selected pharmaceutically-active agent. A method of treating certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed.Other References
| |
